Back to Search
Start Over
Adverse effects related with norepinephrine through short peripheral venous access: Scoping review.
- Source :
-
Enfermeria intensiva [Enferm Intensiva (Engl Ed)] 2023 Oct-Dec; Vol. 34 (4), pp. 218-226. Date of Electronic Publication: 2023 Mar 17. - Publication Year :
- 2023
-
Abstract
- Peripheral administration of norepinephrine is restricted due to the association of extravasation with tissue necrosis.<br />Method: Scoping review with the objective of describing the adverse effects related to the administration of norepinephrine through short peripheral venous access and the characteristics of drug administration in patients hospitalized in ICU, surgery, and emergency services.<br />Results: 12 studies with heterogeneous characteristics by size and type of population were included. The proportion of complications associated with peripheral norepinephrine administration was less than 12% in observational studies and it was less than 2% in those that used doses less than 0.13μg/kg/min, and concentrations less than 22.3μg/mL. The main associated complication was extravasation and there were no cases of tissue necrosis at the venipuncture site, some extravasation cases were treated with phentolamine, terbutaline or topical nitroglycerin. The drug administration time ranged between 1 and 528hours with a weighted mean of 2.78h.<br />Conclusion: The main adverse effect was extravasation, no additional complications occurred, phentolamine and terbutaline seem to be useful, and its availability is a necessity. It is essential for the nursing staff to carry out a close assessment and comprehensive care in patients receiving norepinephrine by peripheral route.<br /> (Copyright © 2022 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2529-9840
- Volume :
- 34
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Enfermeria intensiva
- Publication Type :
- Academic Journal
- Accession number :
- 36935306
- Full Text :
- https://doi.org/10.1016/j.enfie.2022.09.001